Rose Quoted in World IP Review about USPTO’s Section 101 Guidance on Patents
11 May 2020
Senior Counsel Daniel Rose was quoted in the World Intellectual Property Review article, “USPTO’s section 101 guidance puts onus on Congress,” about a recent report by the US Patent and Trademark Office about the damage caused in the wake of the SCOTUS decisions in Alice/Mayo on patentability, but also points to a way out of the quagmire created by those decisions.
Ultimately, there are only two institutions which can provide absolute certainty on patent eligibility: the Supreme Court and Congress. While the Supreme Court appears to have no intention of revisiting the issue as it has consistently refused to review cases dealing with patent-eligibility. Its refusal to do so is “pretty shocking”, Rose said. “The Supreme Court would rather leave it to the Federal Circuit, because they have judges who have scientific and technical backgrounds, or wait for Congress to take action,” Rose argues.
(Subscription Required)
Ultimately, there are only two institutions which can provide absolute certainty on patent eligibility: the Supreme Court and Congress. While the Supreme Court appears to have no intention of revisiting the issue as it has consistently refused to review cases dealing with patent-eligibility. Its refusal to do so is “pretty shocking”, Rose said. “The Supreme Court would rather leave it to the Federal Circuit, because they have judges who have scientific and technical backgrounds, or wait for Congress to take action,” Rose argues.
(Subscription Required)
Related News
25 July 2024
In the News
Donald Schroeder on Groff – ‘Supreme Court decision is inviting a more fact-based analysis’
Foley & Lardner LLP partner Donald Schroeder assessed the impact of the U.S. Supreme Court’s 2023 decision in a religious accommodation case as it returns to the district court in the Law360 article, “A Year After High Court Spotlight, Groff Case Still A Bellwether.”
24 July 2024
In the News
Louis Lehot Featured in Q&A on How Startups Can Prepare for IPO
Foley & Lardner LLP partner Louis Lehot features in the Q&A, "How startups can get in top shape for an IPO, according to Silicon Valley lawyer Louis Lehot," part of Business Insider's Road to IPO' series.
24 July 2024
In the News
Courtenay Brinckerhoff on Patent Cap in Drug Pricing – ‘Hard to predict if this will make a difference’
Foley & Lardner LLP partner Courtenay Brinckerhoff discussed a recent bill passed in the U.S. Senate aimed at lowering drug prices by limiting the number of patents that can be asserted in cases over biosimilars in the Law360 article, “Patent Cap In Drug Pricing Bill Seen As Having Muted Effect.”